Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)

Christian Marth; Miguel Henriques Abreu; Klaus Kaae Andersen; Karoliina M. Aro; Maria de Lurdes Batarda; Dorry Boll; Anne Weng Ekmann-Gade; Ulla-Maija Haltia; Jesper Hansen; Ala Jabri Haug; Claus Hogdall; Jacob Korach; Heini Lassus; Kristina Lindemann; Els Van Nieuwenhuysen; Petronella B. Ottevanger; Stephan Polterauer; Tine Henrichsen Schnack

doi:10.1002/cncr.34350

Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)

Christian Marth, Miguel Henriques Abreu, Klaus Kaae Andersen, Karoliina M. Aro, Maria de Lurdes Batarda, Dorry Boll, Anne Weng Ekmann-Gade, Ulla-Maija Haltia, Jesper Hansen, Ala Jabri Haug, Claus Hogdall, Jacob Korach, Heini Lassus, Kristina Lindemann, Els Van Nieuwenhuysen, Petronella B. Ottevanger, Stephan Polterauer, Tine Henrichsen Schnack

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	Cancer
Volume	128
Issue number	16
Pages (from-to)	3080-3089
Number of pages	10
ISSN	0008-543X
DOIs	https://doi.org/10.1002/cncr.34350
Publication status	Published - 15 Aug 2022
MoE publication type	A1 Journal article-refereed

Fields of Science

bevacizumab
first-line treatment
ovarian cancer
poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor
real-world data
HOMOLOGOUS RECOMBINATION DEFICIENCY
OLAPARIB PLUS BEVACIZUMAB
MAINTENANCE OLAPARIB
RISK
3122 Cancers

Access to Document

10.1002/cncr.34350

Cancer - 2022 - Marth - Real‐life data on treatment and outcomes in advanced ovarian cancer An observational Final published version, 383 KBLicence: CC BY-NC

Cite this

Marth, C., Abreu, M. H., Andersen, K. K., Aro, K. M., de Lurdes Batarda, M., Boll, D., Ekmann-Gade, A. W., Haltia, U-M., Hansen, J., Haug, A. J., Hogdall, C., Korach, J., Lassus, H., Lindemann, K., Van Nieuwenhuysen, E., Ottevanger, P. B., Polterauer, S., & Schnack, T. H. (2022). Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial). Cancer, 128(16), 3080-3089. https://doi.org/10.1002/cncr.34350

@article{050565e55571448b8778b181986e3dd8,

title = "Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)",

keywords = "bevacizumab, first-line treatment, ovarian cancer, poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor, real-world data, HOMOLOGOUS RECOMBINATION DEFICIENCY, OLAPARIB PLUS BEVACIZUMAB, MAINTENANCE OLAPARIB, RISK, 3122 Cancers",

author = "Christian Marth and Abreu, {Miguel Henriques} and Andersen, {Klaus Kaae} and Aro, {Karoliina M.} and {de Lurdes Batarda}, Maria and Dorry Boll and Ekmann-Gade, {Anne Weng} and Ulla-Maija Haltia and Jesper Hansen and Haug, {Ala Jabri} and Claus Hogdall and Jacob Korach and Heini Lassus and Kristina Lindemann and {Van Nieuwenhuysen}, Els and Ottevanger, {Petronella B.} and Stephan Polterauer and Schnack, {Tine Henrichsen}",

year = "2022",

month = aug,

day = "15",

doi = "10.1002/cncr.34350",

language = "English",

volume = "128",

pages = "3080--3089",

journal = "Cancer",

issn = "0008-543X",

publisher = "Wiley",

number = "16",

}

Marth, C, Abreu, MH, Andersen, KK, Aro, KM, de Lurdes Batarda, M, Boll, D, Ekmann-Gade, AW, Haltia, U-M, Hansen, J, Haug, AJ, Hogdall, C, Korach, J, Lassus, H, Lindemann, K, Van Nieuwenhuysen, E, Ottevanger, PB, Polterauer, S & Schnack, TH 2022, 'Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)', Cancer, vol. 128, no. 16, pp. 3080-3089. https://doi.org/10.1002/cncr.34350

TY - JOUR

T1 - Real-life data on treatment and outcomes in advanced ovarian cancer

T2 - An observational, multinational cohort study (RESPONSE trial)

AU - Marth, Christian

AU - Abreu, Miguel Henriques

AU - Andersen, Klaus Kaae

AU - Aro, Karoliina M.

AU - de Lurdes Batarda, Maria

AU - Boll, Dorry

AU - Ekmann-Gade, Anne Weng

AU - Haltia, Ulla-Maija

AU - Hansen, Jesper

AU - Haug, Ala Jabri

AU - Hogdall, Claus

AU - Korach, Jacob

AU - Lassus, Heini

AU - Lindemann, Kristina

AU - Van Nieuwenhuysen, Els

AU - Ottevanger, Petronella B.

AU - Polterauer, Stephan

AU - Schnack, Tine Henrichsen

PY - 2022/8/15

Y1 - 2022/8/15

KW - bevacizumab

KW - first-line treatment

KW - ovarian cancer

KW - poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor

KW - real-world data

KW - HOMOLOGOUS RECOMBINATION DEFICIENCY

KW - OLAPARIB PLUS BEVACIZUMAB

KW - MAINTENANCE OLAPARIB

KW - RISK

KW - 3122 Cancers

U2 - 10.1002/cncr.34350

DO - 10.1002/cncr.34350

M3 - Article

VL - 128

SP - 3080

EP - 3089

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 16

ER -